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Abstract
Background: Measurement of holotranscobalamin 
(holoTC) is increasingly used as a screening test for cobal-
amin (Cbl) deficiency. A level well below the reference 
interval strongly supports a deficient state. We examined 
a 21-year-old woman diagnosed as Cbl deficient because of 
an extremely low holoTC level as measured by the Abbott 
Architect Assay.
Methods: The patient was evaluated for Cbl deficiency 
employing an in-house holoTC method as well as other 
routine markers of Cbl status. Further analyses included 
exploration of the Cbl binding proteins employing gel fil-
tration of a serum sample saturated with 57 Co-labeled Cbl 
and Sanger sequencing of exons 1–9 and the intron-exon 
boundaries of the TCN2 gene, the gene coding for transco-
balamin (TC).
Results: The patient had normal hematological variables 
throughout. Despite initial treatment with Cbl, holoTC as 
measured by the Abbott assay remained low, while holoTC 
measured with the in-house assay was normal, and behaved 
as TC upon gel-filtration. By Sanger sequencing, we detected 
a homozygous single point mutation c.855T > A in exon 6 of 
TCN2, corresponding to a asparagine (Asn) to lysine (Lys) 
substitution in position 267 of the mature protein.
Conclusions: We describe a novel point mutation of the 
TCN2 gene. The mutation does not seem to interfere with 
the function of TC, but the mutation may well explain 
the low level of holoTC detected by the Abbott assay. 
Our results underscores that mutations of TCN2 have 
to be considered when implausible holoTC results are 
obtained.
Keywords: active B12; gene mutation; holoTC; immunoas-
say; TCN2; transcobalamin; vitamin B12.
Introduction
Measurement of circulating holotranscobalamin (holoTC) 
(also named active B12) is increasingly employed as a 
first line screening of patients suspected to suffer from 
vitamin B12 (cobalamin, Cbl) deficiency, and a low value 
of this biomarker supports the presence of a deficient state 
[1–8]. HoloTC denotes the part of circulating Cbl bound 
to transcobalamin (TC), a protein that is essential for 
the transport of Cbl into the cells of the body [8–10]. The 
remaining part of circulating Cbl is bound to haptocorrin, 
a protein of unknown function [9].
Lack of TC is rare. The condition leads to severe Cbl 
deficiency most often diagnosed within the first year of 
life [11, 12], and is caused by mutations in the TCN2 gene. 
So far, small insertion/deletion variants (indels), large 
deletions and mutations leading to exon skipping have 
been identified in TC deficient patients [13]. Healthy indi-
viduals also harbor variations in the TCN2 gene. Specific 
SNPs are associated with minor differences in the plasma 
concentration of holoTC, but have not been associated 
with an impaired Cbl metabolism [5].
The most widely used test of holoTC, “active B12” 
is established on the high throughput Abbott architect 
platform. It employs a sandwich immunoassay based on 
a specific monoclonal antibody [14] that recognizes an 
epitope in the N-terminal part of TC, formed in the course 
of Cbl binding, but not directly involving Cbl as part of the 
epitope itself [15].
Here we describe a patient with undetectable or 
extremely low holoTC levels as measured by the Abbott 
assay, but with no other biomarker values suggesting Cbl 
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deficiency. We show the patient to harbor a mutation of 
the TCN2 gene, likely to alter the epitope of the holoTC 
assay. A possible model of the conformational epitope is 
presented.
Materials and methods
Case report
A 21-year-old woman visited her GP complaining of several non-
specific and not very severe symptoms including fatigue, asthenia, 
headache, sleeplessness, flatulence, acid regurgitation, moderate 
diarrhea, and paresthesia of the fingers. In addition, she presented 
mild psychiatric and family problems, both judged to aggravate the 
somatic symptoms. The final work up gave no somatic explana-
tion for the experienced symptoms. Initial laboratory examinations 
revealed no major abnormalities except for an undetectable holoTC 
( < 5 pmol/L, reference interval  > 40 pmol/L). Cbl, methylmalonic acid 
(MMA) or homocysteine were not requested. The patient was started 
on i.m. hydroxo-Cbl (VITARUBIN, Streuli Pharma AG), 1 mg, and was 
referred to the Hematology out-patient clinic, Bern University Hospi-
tal, Inselspital, Switzerland, for further evaluation of Cbl deficiency. 
Cbl injections had no impact on the clinical symptoms, and 1 month 
after the second i.m. injection of hydroxo-Cbl, holoTC remained low 
(6 pmol/L). At this point, the patient underwent extensive examina-
tion in order to clarify whether the low holoTC indeed mirrors Cbl 
deficiency.
Biochemical analysis
Blood samples were drawn for routine testing adhering to the routine 
of the laboratory. Additional blood samples were collected 7 weeks 
after the third and last injection of 1  mg hydroxo-Cbl for analysis 
of Cbl related variables and the serum was stored at –20 °C. Whole 
EDTA blood for isolation of DNA was stored at –80 °C. Shipment to 
the Department of Clinical Biochemistry, Aarhus University Hospital, 
Denmark, was performed on dry ice.
We used routine laboratory methods for evaluation of hema-
tological variables (Advia 2120i Cellcounter, Siemens Healthcare, 
Zürich, Switzerland), Cbl and creatinine (Cobas 8000 system, Roche 
Diagnostics, Rotkreuz, Switzerland), homocysteine (HPLC, Agilent 
1100 series, Agilent technologies, Basel, Switzerland), MMA (mass 
spectrometry, Agilent GC-MS 6890N/5973N, Agilent technologies, 
Basel, Switzerland), holoTC (AxSYM method on an Architect 2000 
analyzer, Abbott AG, Baar, Switzerland), autoantibodies against 
intrinsic factor (ELISA, Alphadia, B1300, Wavre, Belgium) and 
autoantibodies against parietal cells (ELISA, nova Diagnostics, San 
Diego, CA, USA).
Total TC was measured by a sandwich ELISA assay employ-
ing two polyclonal antibodies specific for TC as described in [16]. 
HoloTC was in addition to the routine method measured by an in-
house ELISA based on removal of apoTC by absorption to B12 coated 
beads followed by analysis of the remaining TC in the supernatant 
(expected to be equal to holoTC) [17]. Haptocorrin was measured by 
an in-house ELISA as previously described [18].
Gel filtration was employed to explore the molecular behav-
ior of TC as described in [19]. In brief, serum labeled with 57 Co-
Cbl ( KemEnTec A/S, Taastrup, Denmark) was run on a Superdex® 
200 HR 10/30 column (GE Healthcare Europe, Broendby, Denmark) 
on a Dionex® ICS-3000 chromatograph (Dionex Corporation, Sunny-
vale, CA, USA) and was eluted with a flow rate of 400 μL/min for 
approximately 70  min employing a Tris buffer (0.1 mol/L) (Sigma 
Aldrich, Broendby, Denmark), 1  mol/L NaCl (Merck A/S Denmark, 
Hellerup, Denmark), 0.5 g/L bovine albumin (Sigma Aldrich), 0.2 
g/L sodium-azide, pH 8.0 (Merck A/S Denmark). The eluted fractions 
were counted in a Wizard Automatic Gamma Counter to monitor the 
elution of 57 Co-Cbl. Molecular mass markers Blue Dextran (Sigma 
Aldrich) and 22 Na (GE Healthcare Europe) were used for determina-
tion of void volume (Vo) and total volume (Vt). Reference serum was 
used for determination of the elution volume of haptocorrin (VHC), 
albumin (Valb) and transcobalamin (VTC).
Genomic DNA was isolated from EDTA blood using the  Maxwell 
16 Blood DNA Purification Kit (Promega Biotech AB, Stockholm, 
 Sweden) following the manufacturer’s instructions. The coding 
regions of the TCN2 gene, encoded by exon 1–9, and the intron-exon 
boundaries, were amplified by PCR (primer sequences available on 
request). The quality of the PCR products were assessed by gel-elec-
trophoresis using a 1.5% ethidium-bromide stained agarose gel (Ultra 
Pure™ Agaraose, Life technologies, Nærum, Denmark). PCR prod-
ucts were purified using the Exo-SAP procedure (Affymetrix, High 
Wycombe, UK). Amplicons were sequenced bidirectional using Big-
Dye terminator version 1.1 (Applied Biosystems, Naerum, Denmark). 
The ethanol-precipitated fragments were separated on an Applied 
Biosystems 3500 Genetic Analyzer. The obtained sequences were 
aligned to the reference sequence NM_000355.2 using SeqScape (ver-
sion 2.7, Applied Biosystems, Naerum, Denmark). Structural analysis 
was done using software PyMol (Schrödinger.com), Swiss-PdbViewer 
(Swiss Institute of Bioinformatics) and the available 3D structure of 
human holoTC [20].
The study was performed in accordance with the Declaration 
of Helsinki and the regulations of the local Ethical Commitee. The 
patient gave written informed consent.
Results
We report data on a patient initially treated with Cbl injec-
tions because of clinical symptoms suggesting Cbl defi-
ciency combined with an unmeasurable level of holoTC. 
During Cbl treatment (total dose of 3 times 1  mg over a 
period of 4.5 months) the patient did not improve. She 
continuously showed low levels of holoTC, but normal 
levels for the hematological variables, total Cbl, MMA and 
homocysteine (Table 1). No autoantibodies against intrin-
sic factor or parietal cells were present.
In order to find an explanation for the low level of 
holoTC as measured by the routine Abbott Architect 
method, we explored the level of total TC and also meas-
ured holoTC employing the in-house ELISA methods 
[16, 17]. Total TC was 590 pmol/L and holoTC 50 pmol/L 
(Table  1). We examined the elution pattern of TC upon 
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Figure 1: Gelfiltration of serum from a patient harboring a TCN2 
mutation.
A serum sample was labeled with 57Co-Cbl to saturate unsaturated 
Cbl binding capacity and separated on a Superdex® 200 HR 10/30 
column (see Materials and method section for details). Indicated 
at the top of the curve is the void volume (V0), the elution volumes 
for haptocorrin (VHC), albumin (Valb), transcobalamin (VTC) ant the 
total volume (Vt). Haptocorrin (HC) and transcobalamin [13] were 
measured in the fractions by ELISA and are indicated in pmol/L. 
57Co-Cbl was counted in the fractions and is indicated in counts per 
minute (CPM).
Table 1: Laboratory data from a patient misdiagnosed as cobalamin deficient due to an initial low level of holoTC. Months after the first 
visit are indicated.
Component  
Reference interval in brackets
  First visita   3 monthsb   4 monthsc   4.5 months   6 months
B-Hemoglobin (121–156), g/L   151   163   157   158   158
S-HoloTC, Abbott ( > 40), pmol/L    < 5     7.0   6.5   5.3
S-Cobalamin (141–489), pmol/L     565     563   592
S-MMA (76–271), nmol/L       148   105  
Homocysteine ( < 15), μmol/L         9  
S-Folate (10.4–42.4), pmol/L   18.5   10.6      
S-Creatinine (45–84), μmol/L   59.4       60  
S-Total TC in-house (610–1400), pmol/L           590
S-HoloTC, in-house ( > 40), pmol/L           50
aAfter first visit treated with 1 mg hydroxo-Cbl i.m.; b1 month after Cbl injection; cat the time of Cbl injection.
gelfiltration of a serum sample saturated with labeled 
Cbl, (Figure 1). The patient’s serum showed distinct peaks 
eluting as TC and haptocorrin both judged by the elution 
profile for 57Co-Cbl and by ELISA assays of the eluted 
fractions.
Sequencing of TCN2, the gene encoding TC, revealed 
a homozygous single point mutation c.855T > A in exon 6, 
leading to an amino acid substitution p.Asn285Lys, cor-
responding to a asparagine (ASN) to lysine (LYS) substitu-
tion in position 267 of the mature protein. The variant is not 
present in the dbSNP (http://www.ncbi.nlm.nih.gov/snp/) 
database and is therefore unlikely to be a normal polymor-
phism. Bioinformatic analysis using PolyPhen2 (http://
genetics.bwh.harvard.edu/pph2/) resulted in a HumVar 
score of 1.000, indicating that the amino acid exchange 
might be damaging. Furthermore, we notice complete 
homozygosity in the entire TCN2 gene sequence (several 
exonic and intronic polymorphic SNPs assayed) (data not 
shown).
Discussion
We report a novel TCN2 mutation detected in a 21-year-
old patient misdiagnosed to suffer from Cbl deficiency 
because of clinical symptoms and an unmeasurable level 
of holoTC by the Abbott assay. The symptoms remained 
after treatment with Cbl injections. No increase in holoTC 
was observed, while all other indicators of Cbl deficiency 
were within the reference interval. In addition, our in-
house assay revealed normal levels of holoTC.
From a clinical point of view, the results warrant 
against diagnosing Cbl deficiency if solely based on the 
measures of holoTC. Currently, the Abbott method for 
measurement of holoTC is used in certain laboratories 
in Switzerland as the initial screening assay. However, 
until further experience using the commercially available 
holoTC assays has accumulated, it is recommended to 
follow the strategy to use at least two markers in order to 
diagnose Cbl deficiency [21].
The Abbott assay and the in-house assay for holoTC 
are based on different principles. While the Abbott 
method depends on an antibody specifically recogniz-
ing holoTC [14], the in-house assay measures holoTC by 
ELISA after removal of all TC not saturated with Cbl [17]. 
Previous studies have shown the two methods to reveal 
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comparable results [22]. This was not the case in our 
patient.
Our patient harbors a mutation predicting an amino 
acid change from Asn to Lys at position 267 in the mature 
protein sequence of TC. The Asn to Lys mutation appears 
to be of importance for the structure of TC as mirrored 
in lack of detection by the Abbott holoTC assay. The 
assay employs a monoclonal antibody that recognizes 
the complex between Cbl and transcobalamin (holoTC), 
but not the Cbl-unsaturated TC. Cbl itself is not part of 
the epitope [15]. Based on the available 3D structure of 
the transcobalamin-Cbl complex [20], we can compare 
the wild type and the mutated TC (Figure 2). The TC 
molecule consists of two large domains (α and β), con-
nected by a flexible link. Cbl assembles the two domains 
together, whereupon the “hairpin” loop of the β-domain 
(between folds β3 and β4) moves under the plane of Cbl 
and contacts both Cbl and the α-domain. The mutated 
Asn-267 from the α-domain is positioned at the begin-
ning of α12 helix and under the b-amide of Cbl (pyrrol 
ring A). Asn-267 interacts with Ser-359 and Asp-393 (both 
from the β-domain), as shown in Figure 2A. The adjacent 
residues Met-270 and L-268 (α12 helix) have hydropho-
bic bonds to the methyl group of pyrrol A (Cbl moiety) 
and the CH2-group of Ser 359, respectively. These bonds 
provide additional stabilization of the contact between 
the two domains. The whole structural element is hidden 
inside the protein and cannot be involved into any direct 
contacts with the antibody. At the same time, Asn-267 
lies at the bottom of a cavity constructed by the two 
loops, connecting the α11–α12 and β7–β8 blocks. This 
cavity slightly expands toward the protein surface and 
ends with the surface residues Asp-262 (α-domain) and 
Lys-397 (β-domain). Both loops are rather flexible and 
are stabilized in the proximity to each other exclusively 
by the inner protein-Cbl and domain-domain interac-
tions. This region is suggested as the conformational 
epitope recognized by a gag-like site on the antibody. 
Mutation of Asn-267 to Lys-267 significantly affects the 
basis of this cavity. The introduced Lys has a longer and 
positively charged residue, which would turn toward the 
negatively charged Asp-393 and clash against it, thereby 
hindering the walls of the cavity from close approach to 
each other (Figure 2B and C). This rearrangement should 
increase the gap of the hole and preclude a tight fitting of 
the gag-like antibody. In addition, the binding character-
istics of Cbl to TC are likely to be affected. Movement of 
the mutated Lys-267 toward Asp-393 and adjustments of 
the bulk Lys-residue are expected to disrupt connections 
of α12 helix to Cbl and the hairpin loop β3–β4. Loss of at 
least one protein-ligand contact plus partially disturbed 
Figure 2: Schematic drawing of transcobalamin showing the pos-
sible effect of the observed Asn-267 Lys mutation on the structure 
of holoTC.
(A) Wild type holoTC. Domains α and β are schematically depicted 
by left and right braces. The central square indicates the corrin ring 
with pyrrol A placed at its upper left corner. The notated α-helices 
and β-folds are situated under the plane of corrin ring. The relevant 
contacts of N267 and the neighboring residues are shown as dotted 
lines. The suggested scheme of interaction between the antibody 
and the conformational epitope is indicated by trapezium and upper 
brace. (B) Mutated TC. Substituted residue K267 swings toward D393 
and widens the cavity. The gag-like antibody does not fit the binding 
site. (C) Close view at the mutated site. The mutated K267 pushes D393 
aside (arrow) and does not allow closer approach of the cavity walls. 
Standard one letter abbreviations are used for the amino acids. 
Notably, N denotes asparagine, K denotes lysine and D denotes 
aspartic acid.
domain-domain fixation would somewhat decrease TC 
affinity for Cbl. The possible alteration of binding of Cbl 
to TC does not critically affect the function of TC, since 
the patient showed values for the metabolic markers 
of Cbl deficiency (MMA and homocysteine) within the 
normal range.
In conclusion, we present data on a patient harbor-
ing a TCN2 mutation that apparently does not prevent 
the function of the protein, but causes falsely low levels 
of holoTC if measured by the commercially availableAb-
bott assay. Our results warrant a caution when relying 
solely on a low level of holoTC for the diagnosis of Cbl 
deficiency.
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